The current TRAM-01 trial is a phase II basket trial including four groups of progressive tumors (NF1-associated gliomas, NF1-associated plexiform neurofibromas, KIAA1540-BRAF fusion gliomas, and other MAPK-ERK pathway–activated gliomas), treated with trametinib monotherapy (NCT03363217). Here, MAPK1 is linked to central nervous system cancer.